VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
VERAXA Biotech AG appointed Christoph Erkel, Ph.D., as Chief Scientific Officer, effective immediately, succeeding Rick Austin, Ph.D., who will leave after a transition period. Erkel was previously Vice President of Research & Development at VERAXA and brings 20 years of experience in antibody therapeutics from his time at MorphoSys AG and Sloning BioTechnology GmbH.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.